Eluminex Biosciences Acquires Zuretinol Acetate from Retinagenix Holdings

Purchase of Assets and Related Global Commercialization Rights for Oral 9-cis-Retinol (Zuretinol) for Rare Forms of Childhood Blindness. Clinical Stage Asset...

Related Keywords

University Of Washington ,Washington ,United States ,Suzhou ,Jiangsu ,China ,San Francisco Bay ,California ,Seattle ,David Saperstein ,Eluminex Biosciences ,Charles Semba ,Marco Northland ,Retinagenix Holdings ,Eluminex Biosciences Ltd Suzhou ,Zuretinol Retinal Rare Pediatric Disease Program ,Drug Administration ,Program Has Received ,Prnewswire Eluminex Biosciences Suzhou Limited ,European Union ,European Medicine Agency ,Related Global Commercialization Rights ,Rare Forms ,Stage Asset Has Potential ,First Approved Oral Therapy ,Congenital Amaurosis ,Retinitis Pigmentosa ,Retinol Acyltransferase ,Pediatric Disease ,Fast Track Designation ,Rare Pediatric Disease Priority Review ,Zuretinol Include Treatment ,Impaired Dark Adaptation ,Night Blindness ,Adult Patients ,Early Dry Age Related Macular Degeneration ,San Francisco Bay Area ,Chief Medical Officer ,Zuretinol Retinal Rare Pediatric Disease ,Orphan Drug Designation ,United States Food ,Fast Track ,Rare Pediatric Disease Priority Review Voucher ,Priority Review ,Nearly Dry ,Suzhou Biobay Industrial Park ,Lilly Asia Ventures ,Hillhouse Capital ,Surgery News ,